Delilah Alvarado

Texas

Writer for @Biopharmadive. Girl with the dragon tattoo. Chicana. Words in @Prismreports, @wearemitu, @YRMedia, @BuiltIn. https://t.co/H1FtFYMFA7

Articles

Women’s health faces growing headwinds, despite jump in venture investment | Healthcare Dive

2 days ago | healthcaredive.com | Delilah Alvarado

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, one biotech CEO said.
Women’s health faces growing headwinds, despite jump in venture investment

3 days ago | biopharmadive.com | Delilah Alvarado

The women’s health field has a long way to go addressing persistent deficits in research and treatment. Common conditions that affect women like endometriosis and polycystic ovarian syndrome remain misunderstood, while maternal mortality in the U.S. than in similarly wealthy countries. Yet there are green shoots. Startups focused on women’s health drew a record amount of venture funding in 2024, extending a run of recent momentum.
FDA follows EMA in limiting use of Valneva shot

4 days ago | biopharmadive.com | Delilah Alvarado

Safety concerns have spurred the Food and Drug Administration and Centers for Disease Control and Prevention to recommend suspending use of Valneva’s chikungunya vaccine in people at least 60 years of age. The recommendation announced Monday comes days after the European Medicines Agency temporarily suspended use of the vaccine, known as Ixchiq, in those over 65 pending an investigation. A committee advising the CDC previously suggested a precaution for use in a similar age group.
FDA set to meet this month on COVID vaccines

1 week ago | biopharmadive.com | Delilah Alvarado

A panel of Food and Drug Adminsitration advisers will meet May 22 to discuss updating the formula of COVID-19 vaccines ahead of the fall and winter season, according to a draft notice posted Wednesday. The Vaccines and Related Biological Products Advisory Committee will provide recommendations on selecting the specific coronavirus variant COVID vaccine manufacturers should target with booster shots. Their advice isn’t binding, but the FDA tends to follow it.
AI specialist Recursion trims pipeline in latest shakeup

1 week ago | biopharmadive.com | Delilah Alvarado

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly earnings report, the company revealed plans to halt development of drugs for cerebral cavernous malformation and neurofibromatosis type II that were in mid-stage testing. Recursion will also pause testing and attempt to license out a therapy it’s been advancing for C. difficile infections.
Moderna combination flu, COVID shot delayed amid FDA scrutiny

2 weeks ago | biopharmadive.com | Delilah Alvarado

The Food and Drug Administration has asked Moderna for additional data before it will consider approving a combination shot the company developed for flu and COVID-19, the latest sign vaccines may face additional regulatory scrutiny under new agency leadership. Alongside first quarter earnings Thursday, the biotechnology company said a U.S. approval decision previously expected this year may now occur in 2026.
Novavax says vaccine application still ‘approvable,’ despite FDA delay

2 weeks ago | biopharmadive.com | Delilah Alvarado

Novavax claims it can surmount the latest regulatory hurdle hindering its quest to win full U.S. clearance of its COVID-19 vaccine, saying Monday it believes its application is still approvable pending an agreement with the Food and Drug Administration on a postmarketing clinical trial. Last week, Novavax revealed the agency had requested what’s known as a postmarketing commitment to further study the shot in clinical tests.
Gilead leans on HIV drugs as oncology sales slow

3 weeks ago | biopharmadive.com | Delilah Alvarado

Dive Brief:Gilead Sciences on Thursday reported $6.7 billion in revenue in the first quarter, missing consensus Wall Street estimates as its cancer drug sales fell short of analyst expectations. Gilead’s oncology portfolio generated $758 million in sales over the first three months of the year, down about 4% compared to the same period in 2024.
CDC panel backs broader use of RSV shots

4 weeks ago | biopharmadive.com | Delilah Alvarado

A panel of advisers to the Centers for Disease Control and Prevention on Wednesday recommended lowering the age at which some people can receive a vaccine for respiratory syncytial virus, but stopped short of advocating for booster shots. Committee members voted nearly unanimously endorse vaccination in adults who are 50 to 59 years of age and at a higher risk of severe RSV-related disease.
CDC panel mulls changes to COVID shot recommendations

1 month ago | biopharmadive.com | Delilah Alvarado

Vaccine advisers to the Centers for Disease Control and Prevention, who met Tuesday for the first time since Robert F. Kennedy Jr. became U.S. health secretary, are considering making changes to the country’s COVID-19 shot guidelines. Committee members weighed whether to maintain the current universal recommendation for everyone six months of age or older, switch to a narrower, risk-based approach or take some combination of the two polices.